Literature DB >> 23727824

Expression of DJ-1 in endometrial cancer: close correlation with clinicopathological features and apoptosis.

Kuanyong Shu1, Zhongqing Xiao, Shenggen Long, Jinjin Yan, Xiaohong Yu, Qizhou Zhu, Tong Mei.   

Abstract

OBJECTIVES: DJ-1 was originally cloned as a putative oncogene capable of transforming NIH3T3 cells in cooperation with H-Ras or c-Myc, which has been implicated in the pathogenesis of some solid tumors. The aim of this study was to investigate the expression and clinical significance of DJ-1 in endometrial cancer and study its effect on cell proliferation and apoptosis in endometrial cancer Ishikawa cells.
METHODS: Reverse transcription polymerase chain reaction and Western blotting were performed to determine the DJ-1 expression in 100 surgical specimens of endometrial cancer tissues, paired tumor-adjacent tissues, and 30 surgical specimens of normal endometrium tissues. The proliferation variety of endometrial cancer Ishikawa cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay after transfecting the interference plasmid pGPU6/GFP/neo-DJ-1-shRNA into Ishikawa cells. Real-time polymerase chain reaction and Western blotting were used to evaluate the effect of interference plasmid on target gene expression. Apoptosis rate was determined by flow cytometry.
RESULTS: DJ-1 expression in endometrial cancer tissues was higher than in tumor-adjacent tissues and normal endometrial tissues. At the same time, it was associated with signs of cancer progression, including differentiation, myometrial invasion depth, and presence of lymph node metastasis. Knocking down DJ-1 promoted the apoptosis of Ishikawa cells.
CONCLUSIONS: High DJ-1 expression seems to be negatively correlated with apoptosis. Meanwhile, it may be part of the mechanisms for the development, invasion, and metastasis in endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23727824     DOI: 10.1097/IGC.0b013e3182959182

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  7 in total

1.  Identification of DJ-1 as a contributor to multidrug resistance in human small-cell lung cancer using proteomic analysis.

Authors:  Hongyi Gao; Yuchun Niu; Man Li; Shun Fang; Linlang Guo
Journal:  Int J Exp Pathol       Date:  2017-06-05       Impact factor: 1.925

2.  The clinical significance of DJ-1 and HE4 in patients with endometrial cancer.

Authors:  Marco Benati; Martina Montagnana; Elisa Danese; Elisa Paviati; Silvia Giudici; Orazio Ruzzenente; Massimo Franchi; Giuseppe Lippi
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

Review 3.  Moving beyond the Tip of the Iceberg: DJ-1 Implications in Cancer Metabolism.

Authors:  Erika Olivo; Marina La Chimia; Jessica Ceramella; Alessia Catalano; Ferdinando Chiaradonna; Maria Stefania Sinicropi; Giovanni Cuda; Domenico Iacopetta; Domenica Scumaci
Journal:  Cells       Date:  2022-04-23       Impact factor: 7.666

4.  DJ-1 activates the noncanonical NF-κB pathway via interaction with Cezanne to inhibit the apoptosis and promote the proliferation of Ishikawa cells.

Authors:  Qi-Zhou Zhu; Hao-Yue Liu; Xiao-Yan Zhao; Le-Jia Qiu; Ting-Ting Zhou; Xue-Ying Wang; He-Ping Chen; Zhong-Qing Xiao
Journal:  Mol Biol Rep       Date:  2021-08-10       Impact factor: 2.316

Review 5.  Cross Talk between Two Antioxidant Systems, Thioredoxin and DJ-1: Consequences for Cancer.

Authors:  Prahlad V Raninga; Giovanna Di Trapani; Kathryn F Tonissen
Journal:  Oncoscience       Date:  2014-01-02

Review 6.  Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression.

Authors:  Wook Jin
Journal:  J Clin Med       Date:  2020-04-26       Impact factor: 4.241

7.  Function Identification of Bovine ACSF3 Gene and Its Association With Lipid Metabolism Traits in Beef Cattle.

Authors:  Wei He; Xibi Fang; Xin Lu; Yue Liu; Guanghui Li; Zhihui Zhao; Junya Li; Runjun Yang
Journal:  Front Vet Sci       Date:  2022-01-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.